Has Inflammation a Significant Implication in Lung Cancer Evolution?
- Conditions
- Lung Neoplasms
- Registration Number
- NCT02484872
- Lead Sponsor
- European Lung Cancer Working Party
- Brief Summary
Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.
- Detailed Description
Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 400
- Lung neoplasms irrespective of stage, histology
- Previously treated lung neoplasms
- A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival Measured from diagnosis until death or last date known to be alive, or at least 48 months
- Secondary Outcome Measures
Name Time Method Complications leading to emergency/ICU From inclusion until death, or a least 48 months Recording any complication leading to consultation at the emergency department or admission into the intensive care unit
Trial Locations
- Locations (1)
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
🇧🇪Brussels, Belgium